Targeting oncogenic KRAS with molecular brush-conjugated antisense oligonucleotides
Open accessThe DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
The mutant form of the guanosine triphosphatase (GTPase) KRAS is a key driver in human tumors but remains a challenging therapeutic target, making KRAS MUT cancers a highly unmet clinical need. Here, we report a class of bottlebrush polyethylene glycol (PEG)–conjugated antisense oligonucleotides (ASOs) for potent in vivo KRAS depletion. Owing to their highly branched architecture, these molecular nanoconstructs suppress nearly all side effects associated with DNA–protein interactions and substantially enhance the pharmacological properties of the ASO, such as plasma pharmacokinetics and tumor uptake. Systemic delivery to mice bearing human non–small-cell lung carcinoma xenografts results in a significant reduction in both KRAS levels and tumor growth, and the antitumor performance well exceeds that of current popular ASO paradigms, such as chemically modified oligonucleotides and PEGylation using linear or slightly branched PEG. Importantly, these conjugates relax the requirement on the ASO chemistry, allowing unmodified, natural phosphodiester ASOs to achieve efficacy comparable to that of chemically modified ones. Both the bottlebrush polymer and its ASO conjugates appear to be safe and well tolerated in mice. Together, these data indicate that the molecular brush–ASO conjugate is a promising therapeutic platform for the treatment of KRAS -driven human cancers and warrant further preclinical and clinical development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Additional emerging modalities include RNA-targeted therapeutics, antisense oligonucleotides, siRNA-based suppression [65,66], neoantigen vaccines [67,68], and adoptive T-cell therapies targeting mutant KRAS-derived epitopes [69,70].”
From Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies (2026) · cites this paper as [65]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular dynamics with coupling to an external bath
Berendsen, H. J. C., Postma, J. P. M., van Gunsteren, W. F., DiNola, A., & Haak, J. R. (1984) · The Journal of Chemical Physics · doi:10.1063/1.448118 · Cited by 30,700 · cited 1×
“The temperature was controlled at 310 K using the Berendsen thermostat while the pressure was controlled at 1 atm using the Berendsen barostat (57).”
MethodGROMACS: Fast, flexible, and free
Van Der Spoel, D., Lindahl, E., Hess, B., Groenhof, G., Mark, A. E., & Berendsen, H. J. C. (2005) · Journal of Computational Chemistry · doi:10.1002/jcc.20291 · Cited by 19,182
The MARTINI Force Field: Coarse Grained Model for Biomolecular Simulations
Marrink, S. J., Risselada, H. J., Yefimov, S., Tieleman, D. P., & de Vries, A. H. (2007) · The Journal of Physical Chemistry B · doi:10.1021/jp071097f · Cited by 5,562
Effect of pegylation on pharmaceuticals
Harris, J. M., & Chess, R. B. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1033 · Cited by 3,431 · cited 1×
“Importantly, the observed physiochemical and biopharmaceutical enhancements over naked nucleic acids are realized using predominantly PEG, which is generally regarded as safe for therapeutic applications (37).”
BackgroundExosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer
Kamerkar, S., LeBleu, V. S., Sugimoto, H., Yang, S., Ruivo, C. F., Melo, S. A., Lee, J. J., & Kalluri, R. (2017) · Nature · doi:10.1038/nature22341 · Cited by 2,639 · cited 1×
“The difficulty in developing small-molecule inhibitors for KRAS has heightened the importance of alternative methods targeting the oncogene, for example using antisense oligonucleotides (ASOs) (10), which offer a possibility to yield drugs for targets that have proven to be intractable to traditional drug modalities (…”
BackgroundK-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557 · cited 1×
“However, in 2013, it was shown that the cysteine residue of the G12C mutant give rise to a new pocket that can be selectively targeted by small-molecule binders (3, 7).”
BackgroundOncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism
Ying, H., Kimmelman, A. C., Lyssiotis, C. A., Hua, S., Chu, G. C., Fletcher-Sananikone, E., Locasale, J. W., Son, J., Zhang, H., Coloff, J. L., et al. (2012) · Cell · doi:10.1016/j.cell.2012.01.058 · Cited by 2,043
Self-citationAdvances in oligonucleotide drug delivery
Roberts, T. C., Langer, R., & Wood, M. J. A. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0075-7 · Cited by 2,027
Drugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997
RAS Proteins and Their Regulators in Human Disease
Simanshu, D. K., Nissley, D. V., & McCormick, F. (2017) · Cell · doi:10.1016/j.cell.2017.06.009 · Cited by 1,943 · cited 1×
“The missense mutation of KRAS aberrantly activates the protein into a hyperexcitable state by attenuating its guanosine triphosphatase (GTPase) activity, which results in an accretion of GTP-bound, activated KRAS and persistent activation of downstream signaling pathways (2).”
Background
Cited by
Chemically Modified Platforms for Better RNA Therapeutics
Shi, Y., Zhen, X., Zhang, Y., Li, Y., Koo, S., Saiding, Q., Kong, N., Liu, G., Chen, W., & Tao, W. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00611 · Cited by 172
Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges
Choucair, K., Imtiaz, H., Uddin, M. H., Nagasaka, M., Al-Hallak, M. N., Philip, P. A., El-Rayes, B., Pasche, B., & Azmi, A. S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02473-8 · Cited by 80
Lu, J., Dai, Y., He, Y., Zhang, T., Zhang, J., Chen, X., Jiang, C., & Lu, H. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.3c11914 · Cited by 51
New prospectives on treatment opportunities in RASopathies
Gelb, B. D., Yohe, M. E., Wolf, C. M., & Andelfinger, G. (2022) · American Journal of Medical Genetics Part C Seminars in Medical Genetics · doi:10.1002/ajmg.c.32024 · Cited by 43
Xue, L., Xiong, X., Zhao, G., Arocho, W. A. M., Palanki, R., Xiao, Z., Han, X., Yoon, I., Figueroa‐Espada, C. G., Xu, J., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.4c10265 · Cited by 43
A Long‐Circulating Vector for Aptamers Based upon Polyphosphodiester‐Backboned Molecular Brushes
Wang, Y., Wang, D., Lin, J., Lyu, Z., Chen, P., Sun, T., Xue, C., Mojtabavi, M., Vedadghavami, A., Zhang, Z., et al. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202204576 · Cited by 26
Self-citationHigh-content tailoring strategy to improve the multifunctionality of functional nucleic acids
Chen, K., Zhu, L., Li, J., Zhang, Y., Yu, Y., Wang, X., Wei, W., Huang, K., & Xu, W. (2024) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2024.116494 · Cited by 23
He, Z.-J., Huang, B., & Cai, L. (2024) · ACS Nano · doi:10.1021/acsnano.4c01983 · Cited by 22
Sandai, D. A., Du, Z., Zhang, H., & Sun, Q. (2025) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2025.2555278 · Cited by 24
Molecular Structure of Foldable Bottlebrush Polymers in Melts
Cai, L. (2025) · Macromolecules · doi:10.1021/acs.macromol.4c02981 · Cited by 19
Connecting the dots: LncRNAs in the KRAS pathway and cancer
Maqbool, M., Hussain, M. S., Bisht, A. S., Kumari, A., Kamran, A., Sultana, A., Kumar, R., Khan, Y., & Gupta, G. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155570 · Cited by 19
Enabling safer, more potent oligonucleotide therapeutics with bottlebrush polymer conjugates
Chen, P., Wei, Y., Sun, T., Lin, J., & Zhang, K. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.12.035 · Cited by 17
Self-citationThe Small RNA Landscape in NSCLC: Current Therapeutic Applications and Progresses
Ciccone, G., Ibba, M. L., Coppola, G., Catuogno, S., & Esposito, C. L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076121 · Cited by 17
“By using NSCLC cell models, authors showed that this molecule allows a higher antisense efficacy than unassembled hairpins and displays an improved retention time in vivo [38].”
BackgroundMethodPanda, P., Kar, S. S., & Mohapatra, R. (2024) · Next Materials · doi:10.1016/j.nxmate.2024.100336 · Cited by 18
Delivery of nucleic acid drugs for tumor therapy: Opportunities and challenges
Sun, D., Tan, W., Zhao, J., Tian, Y., Li, S., Zhang, Z., Dong, X., Liu, X., Liu, N., Jiao, P., et al. (2024) · Fundamental Research · doi:10.1016/j.fmre.2023.11.020 · Cited by 15
Self-citationNanoparticle-mediated universal CAR-T therapy
Fan, M., Zheng, J., Huang, Y., Lu, M., Shang, Z., & Du, M. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124779 · Cited by 13
Bottlebrush Polymers with Sequence-Controlled Backbones for Enhanced Oligonucleotide Delivery
Wei, Y., Chen, P., Ren, M., Li, D., Lin, J., Sun, T., Wang, Y., Yang, S., Nenopoulos, C., Oetheimer, C., et al. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c13285 · Cited by 13
Self-citationShao, L., Zhang, H., Sun, L., Ning, L., Sun, X., Qin, C., Xu, W., Xu, R., & Jia, F. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202405202 · Cited by 13
Self-citationSelf-assembled DNA nanodevices for intelligent biosensing
Chen, Y., Tian, R., Zhang, Y., Ding, B., & Jiang, Q. (2025) · Nanoscale Horizons · doi:10.1039/d5nh00446b · Cited by 11
Nucleic Acid-Based Approaches to Tackle KRAS Mutant Cancers
Kim, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242316933 · Cited by 12
“…acid-based therapies have the potential to substantially expand the scope of targets and clinical applications in the field of medicine (Figure 2) [31–34]. siRNAs are short, double-stranded RNAs (dsRNAs), typically 20 to 24 nucleotides in length. siRNAs are short, double-stranded RNAs (dsRNAs),…”
BackgroundZhang, L., Wang, Y., Chen, P., Wang, D., Sun, T., Zhang, Z., Wang, R., Kang, X., Yang, F., Lü, H., et al. (2023) · RSC Chemical Biology · doi:10.1039/d2cb00149g · Cited by 10
Self-citationRegulation and Therapeutic Application of Long non-Coding RNA in Tumor Angiogenesis
Zhang, S., Xia, Y., Chen, W., Dong, H., Cui, B., Liu, C., Liu, Z., Wang, F., & Du, J. (2024) · Technology in Cancer Research & Treatment · doi:10.1177/15330338241273239 · Cited by 10
“108 Chemical modi fi - cations could improve delivery potency.”
BackgroundAntisense oligonucleotide therapies for monogenic disorders
Krey, I., Ferro, I., & Wagner, M. (2025) · Medizinische Genetik · doi:10.1515/medgen-2025-2025 · Cited by 9
Shirinichi, F., Ibrahim, T., Rodriguez, M., & Sun, H. R. (2022) · Journal of Polymer Science · doi:10.1002/pol.20220614 · Cited by 8
Phung, C. D., Tran, T. T. T., Yeo, B. Z. J., Prajogo, R. C., Saudjana, E., Yeo, E. Y. M., Gao, C. J., Nguyen, P. H. D., Jayasinghe, M. K., Dang, X. T. T., et al. (2025) · Theranostics · doi:10.7150/thno.105519 · Cited by 7
“ASOs targeting KRAS have shown promise in several studies, demonstrating efficacy in suppressing tumor growth [19–21].”
Diagnostic and Therapeutic Advances of RNAs in Precision Medicine of Gastrointestinal Tumors
Liu, R., Zhou, J., Chen, X., Zhang, J., Chen, Q., Liu, X., & Yao, K. (2024) · Biomedicines · doi:10.3390/biomedicines13010047 · Cited by 7
Delivery science: Its increasing importance for the next generation of medicines
Ashford, M. B., & Bak, A. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114663 · Cited by 5
Synthesis and biophysical properties of tetravalent PEG-conjugated antisense oligonucleotide
Chowdhury, T. R., Taufiq, T., Ishida, K., Islam, M. A., Kasahara, Y., Osawa, T., & Obika, S. (2022) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2022.117149 · Cited by 5
One-pot synthesis of dynamically cross-linked polymers for serum-resistant nucleic acid delivery
Sun, Z., Ren, M., Shan, B., Yang, Q., Zhao, Z., Liu, X., & Yin, L. (2023) · Biomaterials Science · doi:10.1039/d3bm00685a · Cited by 5
Self-citationRen, G., Xu, R., Zhao, L., Ning, L., Zhang, H., Sun, X., Lu, Z., Liu, X., & Jia, F. (2026) · Advanced Materials · doi:10.1002/adma.73308 · Cited by 4
Self-citationPEG-ASO conjugates for efficient targeted delivery and migration inhibition in Cancer cell
Zhao, C., Li, X., He, Z., Ye, C., Chen, F., & Cheng, J. R. (2025) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2025.130208 · Cited by 3
RNA Therapeutics in Viral Infections and Cancer: Mechanisms, Challenges, and Prospects: A Review
Generalov, E. A., Shevelev, A. B., Romanov, D., Tarasova, O. A., & Pozdniakova, N. V. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18040431 · Cited by 3
Nucleic Acid Therapeutics for “Undruggable” Cancer Targets: Mechanisms, Challenges, and Prospects
Xu, F., Wang, K. J., 卢开忠, Hou, T., Chen, Y., Wang, X., & Jin, H. (2026) · Advanced Science · doi:10.1002/advs.75837 · Cited by 4
“However, despite decades of intensive effort, direct targeting therapies against them have made limited clinical progress, representing a major bottleneck in cancer treatment that demands innovative solutions [ 6 ].”
A Long‐Circulating Vector for Aptamers Based upon Polyphosphodiester‐Backboned Molecular Brushes
Wang, Y., Wang, D., Lin, J., Lyu, Z., Chen, P., Sun, T., Xue, C., Mojtabavi, M., Vedadghavami, A., Zhang, Z., et al. (2022) · Angewandte Chemie · doi:10.1002/ange.202204576 · Cited by 3
Self-citationWang, C., Wang, C., Xiao, C., Zhang, W., Guo, Y. H., Qu, M., Song, Q., Qi, X., & Zou, B. (2025) · Small · doi:10.1002/smll.202410146 · Cited by 3
Sun, T., Lin, J., Xue, C., Wang, Y., Chen, P., Wei, Y., Xu, G., Sidonia, A., Nenopoulos, C., Tashkandi, H., et al. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202405083 · Cited by 2
Self-citationWen, Y., Zhang, N., Sun, S., Yang, C. R., Cheng, X., Mi, S., Shi, G., Huang, X., You, W., & Lu, X. (2026) · Polymer science & technology. · doi:10.1021/polymscitech.6c00029 · Cited by 2
Self-citationZhang, C. L., Yuan, Z., Zhou, J., Yan, H., Liu, Z., Zhang, X., Zhang, Y., Zhang, S., Zhu, L., Wang, D., et al. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04469-0 · Cited by 1
“Free siRNA exhibited negligible cellular uptake, likely due to its polyanionic nature and poor membrane permeability [36].”
Self-citationYuan, B., Tian, Y., Lin, W.-B., Bi, C., Zhang, Y., Jin, Y., Maatouk, B. I., Khashab, N. M., & Li, M. (2026) · Nature Communications · doi:10.1038/s41467-026-73901-8 · Cited by 1
“With these advantages, Cy5-modi fi ed ASOs (which speci fi cally target RNA to knock down gene expression) are emerging in drug development 88,89 , encouraging further investigation of 5 ′ Cy5-ssODNs for CRISPR-based genome editing in clinical settings.”
RNA therapeutics: current status and future directions
Yang, B., Sedano, M. J., Perez, K. L., Vijayaraghavan, M., Reid, V. A., Yallapu, M. M., Chauhan, S. C., Dhandayuthapani, S., Ramos, E., & Gadad, S. S. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-03032-5 · Cited by 1
Drug-Grafted DNA for Cancer Therapy
Wang, D., Zhang, X., & Zhu, X. (2023) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.3c01321 · Cited by 1
Self-citationA Manual for Genome and Transcriptome Engineering
Doctor, Y., Sanghvi, M., & Mali, P. (2024) · IEEE Reviews in Biomedical Engineering · doi:10.1109/rbme.2024.3494715 · Cited by 1
Kano, Y. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27135796
“Additional emerging modalities include RNA-targeted therapeutics, antisense oligonucleotides, siRNA-based suppression [65,66], neoantigen vaccines [67,68], and adoptive T-cell therapies targeting mutant KRAS-derived epitopes [69,70].”
Point Mutation Selective Photo-Cross-Linking Reactions by Diazirine-Derivatized ODNs
Kobata, K., Unita, D., Matsuo, K., Waku, T., & Kobori, A. (2025) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.4c02493
K-RAS VE Gα DİMERİZASYONUNDA G-DOMAIN BÖLGESİNİN ROLÜ
Aydın, İ. (2024) · OpenMETU (Middle East Technical University)
Kivunga, F., Baylot, V., Verget, J., Pereira, H., Vialet, B., Korczak, P., Dessolin, J., & Barthélémy, P. (2026) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5c00627
Sequence-defined Digital Bottlebrush Polymers for Programmable Oligonucleotide Delivery
Lin, J., Sun, T., Wei, Y., Xue, C., Xu, G., Xu, G., Chen, P., Wang, Y., Yang, S., Cavazos, C., et al. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.6c09537
Self-citationDevelopment of a Novel Polymer-based Drug Delivery System
Wang, A. (2026) · International journal of high school research · doi:10.36838/ijhsr816.18
Chen, Q., Ding, F., Zhang, S., Hu, X., Shi, Q., Li, M., Li, J., Zhu, Y. J., Zuo, X., Mou, S., et al. (2026) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6c14185
Metadata
- Authors
- Wang, D., Wang, Q., Wang, Y., Chen, P., Lu, X., Jia, F., Sun, Y., Sun, T., Zhang, L., Che, F., He, J., Lian, L., Morano, G., Shen, M., Ren, M., Dong, S. S., Zhao, J. J., & Zhang, K.
- Affiliations
- Northeastern University (US)
- Harvard University (US)
- Koch Institute for Integrative Cancer Research At MIT (US)
- Corresponding author
- Zhao, Jean J.
- Zhang, Ke
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2022-07-14
- Volume
- 119
- Issue
- 29
- Pages
- e2113180119-e2113180119
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC9304022
- OpenAlex
- W4285387133
- Cited by
- 43
- References
- 57
- Citations by year
- 2026: 10 · 2025: 10 · 2024: 12 · 2023: 5 · 2022: 6
- FWCI
- 2.69
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- HHS | NIH | National Cancer Institute (1R01CA251730)
- HHS | NIH | National Institute of General Medical Sciences (1R01GM121612)
- National Science Foundation (2004947)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Physical Sciences › Materials Science › Polymers and Plastics › Dendrimers and Hyperbranched Polymers
- Keywords
- KRAS mutation, antisense oligonucleotides, bottlebrush polymers, molecular brushes, non-small cell lung cancer, pharmacokinetics, tumor uptake, antitumor efficacy, drug delivery
- MeSH terms
- Animals, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Polyethylene Glycols, Proto-Oncogene Proteins p21(ras), Oligonucleotides, Antisense, Xenograft Model Antitumor Assays, Mice, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.